Phio Pharmaceuticals Initiates Collaborative Clinical Trial With PH-762, AgonOx's Tumor Infiltrating Lymphocyte And Providence Cancer Institute
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals has initiated a collaborative clinical trial with AgonOx's tumor infiltrating lymphocyte (TIL) and Providence Cancer Institute using PH-762, a potential cancer treatment. The trial aims to evaluate the safety and efficacy of the combination therapy.
May 24, 2023 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals initiates a clinical trial with AgonOx's TIL and Providence Cancer Institute using PH-762, potentially benefiting the company if the trial is successful.
The initiation of the clinical trial with AgonOx's TIL and Providence Cancer Institute using PH-762 is a significant development for Phio Pharmaceuticals. If the trial demonstrates safety and efficacy, it could lead to increased interest in the company's stock and potential future revenue from the therapy. This news is highly relevant to PHIO and important for investors, as successful trials can have a positive impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100